143 related articles for article (PubMed ID: 22503318)
1. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy.
Armstrong L; Davydova J; Brown E; Han J; Yamamoto M; Vickers SM
Surgery; 2012 Jul; 152(1):114-22. PubMed ID: 22503318
[TBL] [Abstract][Full Text] [Related]
2. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.
Armstrong L; Arrington A; Han J; Gavrikova T; Brown E; Yamamoto M; Vickers SM; Davydova J
Am J Surg; 2012 Nov; 204(5):741-50. PubMed ID: 22748294
[TBL] [Abstract][Full Text] [Related]
3. Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma.
LaRocca CJ; Salzwedel AO; Sato-Dahlman M; Romanenko MV; Andrade R; Davydova J; Yamamoto M
Ann Surg Oncol; 2021 Dec; 28(13):8556-8564. PubMed ID: 34324109
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.
LaRocca CJ; Han J; Gavrikova T; Armstrong L; Oliveira AR; Shanley R; Vickers SM; Yamamoto M; Davydova J
Surgery; 2015 May; 157(5):888-98. PubMed ID: 25731784
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
[TBL] [Abstract][Full Text] [Related]
6. Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model.
Shinoda S; Sharma NS; Nakamura N; Inoko K; Sato-Dahlman M; Murugan P; Davydova J; Yamamoto M
Cancer Sci; 2023 Sep; 114(9):3759-3769. PubMed ID: 37439437
[TBL] [Abstract][Full Text] [Related]
7. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy.
Monsurrò V; Beghelli S; Wang R; Barbi S; Coin S; Di Pasquale G; Bersani S; Castellucci M; Sorio C; Eleuteri S; Worschech A; Chiorini JA; Pederzoli P; Alter H; Marincola FM; Scarpa A
J Transl Med; 2010 Jan; 8():10. PubMed ID: 20113473
[TBL] [Abstract][Full Text] [Related]
8. Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.
Toyoda E; Doi R; Kami K; Mori T; Ito D; Koizumi M; Kida A; Nagai K; Ito T; Masui T; Wada M; Tagawa M; Uemoto S
J Exp Clin Cancer Res; 2008 Aug; 27(1):30. PubMed ID: 18717994
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
[TBL] [Abstract][Full Text] [Related]
10. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
[TBL] [Abstract][Full Text] [Related]
11. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells.
Kimura J; Ono HA; Kosaka T; Nagashima Y; Hirai S; Ohno S; Aoki K; Julia D; Yamamoto M; Kunisaki C; Endo I
Cancer Sci; 2013 Aug; 104(8):1083-90. PubMed ID: 23679574
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.
Ohashi M; Yoshida K; Kushida M; Miura Y; Ohnami S; Ikarashi Y; Kitade Y; Yoshida T; Aoki K
Br J Cancer; 2005 Aug; 93(4):441-9. PubMed ID: 16106250
[TBL] [Abstract][Full Text] [Related]
13. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
14. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT
Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
[TBL] [Abstract][Full Text] [Related]
17. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
20. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
